肿瘤综合治疗电子杂志2024，Vol.10Issue(2)：69-98,30.DOI:10.12151/JMCM.2024.02-08
淋巴瘤免疫治疗中国专家共识(2024年版)
Chinese expert consensus on immunotherapy of lymphoma(2024 edition)
中国老年保健协会肿瘤免疫治疗专业委员会 1李志铭 1张会来 1周辉 1吴辉菁 1李玉华 1姜文奇1
作者信息
摘要
Abstract
Lymphoma is a malignancy of the immune system originating in the lymph nodes and lymphoid tissue,has seen significant advancements in treatment through immunotherapy.There remains no relevant consensus regarding its standard clinical application in China.To address this gap,the Tumor Immunotherapy Professional Committee of China Geriatric Health Association mobilized experts from various fields to conduct a series of in-depth discussions on current evidence and clinical studies of immunotherapy.All collaborative efforts have contributed to this Chinese expert consensus on immunotherapy of lymphoma(2024 version).This consensus comprehensively covers research and applications of immunotherapy for lymphoma,including monoclonal antibodies,bispecific antibodies,immune checkpoint inhibitors,antibody-drug conjugate,immunomodulatory drugs,and cellular therapy.This consensus will facilitate standardizing clinical practices in immunotherapy for lymphoma malignancies.关键词
淋巴瘤/免疫治疗/中国专家共识/抗体/细胞治疗Key words
Lymphoma/Immunotherapy/Chinese expert consensus/Antibodies/Cellular therapy引用本文复制引用
中国老年保健协会肿瘤免疫治疗专业委员会,李志铭,张会来,周辉,吴辉菁,李玉华,姜文奇..淋巴瘤免疫治疗中国专家共识(2024年版)[J].肿瘤综合治疗电子杂志,2024,10(2):69-98,30.
